Expert Perspectives in Testing and Targeted Therapy: Managing Patients with EGFR Exon20+ NSCLC : Episode 8
Evolving Management of EGFR Exon20+ NSCLC: Future Directions in Care
Closing out their discussion on EGFR Exon20+ non–small cell lung cancer, Joshua Sabari, MD, and Misako Nagasaka, MD, share excitement for future evolutions in the treatment paradigm.
EP: 1.Paradigm of NGS Testing in Patients With Advanced NSCLC
EP: 2.Uncommon EGFR Mutations in Advanced Non–Small Cell Lung Cancer
EP: 3.First- and Second-Line Treatment Options for EGFR Exon20+ NSCLC
EP: 4.Trial Data and Experience With Amivantamab in EGFR Exon20+ NSCLC
EP: 5.EGFR Exon20+ NSCLC: Trial Data With Mobocertinib
EP: 6.Factors in Selecting Novel Therapy for Patients With EGFR Exon20+ NSCLC
EP: 7.Advanced NSCLC: CNS Penetration With Novel EGFR TKI Therapy
Now Viewing
EP: 8.Evolving Management of EGFR Exon20+ NSCLC: Future Directions in Care
EP: 9.Amivantamab vs Mobocertinib in Exon 20 NSCLC
EP: 10.Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC
Recent Videos
Related Content
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Georgios Evangelou, MD, MSc;Ioannis Vamvakaris, MD, PhD, MSc;Irene Konstantopoulou, PhD;Konstantinos Syrigos, PhD
July 10th 2024Article
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
